## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1-112. Canceled.
- 113. (Currently amended) An isolated anti-mesothelin antibody comprising a variable heavy  $(V_H)$   $("V_H")$  chain and a variable light  $("V_L")$  chain, which  $V_H$  and  $V_L$  chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).
- 114. (Previously presented) An antibody of claim 113, wherein said V<sub>H</sub> and V<sub>L</sub> chains comprise framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).
- 115. (Previously presented) An antibody of claim 113, wherein said antibody is a single chain Fv ("scFv").
- 116. (Previously presented) An antibody of claim 115, wherein said scFv has  $V_H$  and  $V_L$  chains joined by a peptide linker.
- 117. (Previously presented) An antibody of claim 116, wherein said peptide linker has the sequence of SEQ ID NO:6.
- 118. (Previously presented) An scFv of claim 115, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).
- 119. (Previously presented) An antibody of claim 113, which is a disulfide stabilized Fv ("dsFv").

- 120. (Previously presented) A dsFv of claim 119, having a V<sub>L</sub> chain containing a cysteine at position 42, 43, 44, 45, 46, 98, 99, 100, or 101, such positions being determined in accordance with the numbering scheme published by Kabat and Wu, and a V<sub>H</sub> chain containing a cysteine at position 43, 44, 45, 46, 47, 103, 104, 105 or 106, such positions being determined in accordance with the numbering scheme published by Kabat and Wu.
- 121. (Previously presented) An antibody of claim 113, wherein said  $V_H$  and  $V_L$  chains are encoded by SEQ ID NO:1.
  - 122. Canceled.
- 123. (Previously presented) An antibody of claim 113, further wherein said antibody is labeled with a detectable label.
- 124. (Previously presented) An scFv of claim 115, further wherein said scFv is labeled with a detectable label.
- 125. (Previously presented) A dsFv of claim 119, which dsFv is labeled with a detectable label.
- 126. (Previously presented) An antibody of claim 113, further wherein said antibody is attached or fused to a therapeutic agent.
- 127. (Previously presented) An scFv of claim 115, further wherein said scFv is attached or fused to a therapeutic agent.
- 128. (Previously presented) A dsFv of claim 119, further wherein said dsFv is attached or fused to a therapeutic agent.

- 129. (Previously presented) An antibody of claim 126, wherein said therapeutic agent is a toxin.
- 130. (Previously presented) An scFv of claim 127, wherein said therapeutic agent is a toxin.
- 131. (Previously presented) A dsFv of claim 128, further wherein said therapeutic agent is a toxin.
- 132. (Previously presented) An antibody of claim 129, wherein said toxin is a *Pseudomonas* exotoxin or cytotoxic fragment or mutant thereof.
- 133. (Previously presented) An scFv of claim 130, wherein said toxin is a *Pseudomonas* exotoxin or cytotoxic fragment or mutant thereof.
- 134. (Previously presented) A dsFv of claim 131, wherein said toxin is a *Pseudomonas* exotoxin or cytotoxic fragment or mutant thereof.
- 135. (Previously presented) An isolated anti-mesothelin antibody comprising a variable heavy (" $V_H$ ") chain which  $V_H$  chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).
- 136. (Previously presented) An antibody of claim 135, wherein said  $V_H$  chain has the sequence set forth in Figure 1 (SEQ ID NO:5).
- 137. (Previously presented) An antibody of claim 135, wherein said antibody is attached or fused to a therapeutic agent or detectable label.

- 138. (Previously presented) An antibody of claim 135, wherein said therapeutic agent is a toxin.
- 139. (Previously presented) An antibody of claim 138, wherein said toxin is a *Pseudomonas* exotoxin or cytotoxic fragment or mutant thereof.
- 140. (Previously presented) An isolated anti-mesothelin antibody comprising a variable light (" $V_L$ ") chain which  $V_L$  chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).
- 141. (Previously presented) An antibody of claim 140, wherein said  $V_L$  chain has the sequence set forth in Figure 1 (SEQ ID NO:5).
- 142. (Previously presented) An antibody of claim 140, wherein said antibody is attached or fused to a therapeutic agent or detectable label.
- 143. (Previously presented) An antibody of claim 142, wherein said therapeutic agent is a toxin.
- 144. (Previously presented) An antibody of claim 143, wherein said toxin is a *Pseudomonas* exotoxin or cytotoxic fragment or mutant thereof.
- 145. (Previously presented) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V<sub>H</sub>") chain and a variable light ("V<sub>L</sub>") chain, which V<sub>H</sub> and VL chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

- 146. (Previously presented) A composition of claim 145, wherein said  $V_H$  and  $V_L$  chains comprise framework regions ("FRs") as shown in Figure 1 (SEQ ID NO:5).
- 147. (Previously presented) A composition of claim 145, wherein said antibody is a single chain Fv ("scFv").
- 148. (Previously presented) A composition of claim 147, wherein said scFv has  $V_H$  and  $V_L$  chains joined by a peptide linker.
- 149. (Previously presented) A composition of claim 145, wherein said peptide linker has the sequence of SEQ ID NO:6.
- 150. (Previously presented) A composition of claim 147, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).
- 151. (Previously presented) A composition of claim 145, wherein said antibody is a disulfide stabilized Fv ("dsFv").
- 152. (Previously presented) A composition of claim 145, wherein said therapeutic agent is a toxin.
- 153. (Previously presented) A composition of claim 152, wherein said toxin is a modified *Pseudomonas* exotoxin or a cytotoxic fragment or mutant thereof.
- 154. (Previously presented) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable

label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V<sub>H</sub>") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

- 155. (Previously presented) A composition of claim 154, wherein said  $V_H$  chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).
- 156. (Previously presented) A composition of claim 154, wherein said therapeutic agent is a toxin.
- 157. (Previously presented) A composition of claim 154, wherein said toxin is a modified *Pseudomonas* exotoxin or a cytotoxic fragment or mutant thereof.
- 158. (Previously presented) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable light ("V<sub>L</sub>") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).
- 159. (Previously presented) A composition of claim 158, wherein said  $V_L$  chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).
- 160. (Previously presented) A composition of claim 158, wherein said therapeutic agent is a toxin.
- 161. (Previously presented) A composition of claim 158, wherein said toxin is a modified *Pseudomonas* exotoxin or a cytotoxic fragment or mutant thereof.
- 162. (Previously presented) A kit for detecting mesothelin on the surface of cells, said kit comprising:

- (i) anti-mesothelin antibody comprising a variable heavy  $(V_H)$  chain and a variable light (" $V_L$ ") chain, which  $V_H$  and  $V_L$  chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5); and,
- (ii) instructions printed on a tangible medium, said instructions describing methods of using and said antibody for detecting mesothelin on the surface of cells.
- 163. (Previously presented) A kit of claim 162, wherein said  $V_H$  and  $V_L$  chains of said antibody have the sequence set forth in Figure 1 (SEQ ID NO:5).
- 164. (Previously presented) A kit of claim 162, wherein said antibody is a scFv.
- 165. (Previously presented) A kit of claim 164, wherein said scFv has the sequence set forth in SEQ ID NO:5.